Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus
Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus
复制标题
DOI：
10.1016/j.ygyno.2008.04.002
复制
发表时间：
2008-08-01
影响因子：
4.7
通讯作者：
Lu, Karen
中科院分区：
文献类型：
--
作者：
Moore, Richard G.;Brown, Amy K.;Lu, Karen
目标。需要对子宫内膜癌具有更高敏感性和特异性的肿瘤标志物来帮助监测治疗反应和检测复发疾病。目前，肿瘤标志物CA125被用于这一作用，但价值有限。本研究的目的是检测几种新的肿瘤标志物HE4、SMRP、CA72.4和CA125在子宫内膜样腺癌患者中的水平。对手术分期的子宫内膜样腺癌患者术前血清标本进行HE4、SMRP、CA72-4和CA125水平分析。对照样本来自健康的绝经后妇女。为每个肿瘤标志物和所有组合构建Logistic回归模型和受试者工作特征(ROC)曲线，并进行交叉验证分析，获得集合特异度分别为90%、95%和98%的平均敏感度。本文分析了156例健康人和171例子宫内膜癌患者(1期122例，II期17例，III期26例，IV期6例)的血清标本。在95%的特异度下，区分健康受试者和所有癌症阶段的敏感度HE4为45.5%，CA125为24.6%。对于I期疾病，HE4的敏感性比CA125提高了17.1%。HE4在子宫内膜癌各期均升高，对早期子宫内膜癌较CA125更敏感。进一步研究HE4作为早期发现复发子宫内膜癌和监测治疗反应的标志物是有必要的。(C)2008 Elsevier Inc.保留所有权利。
Objective. Tumor markers with increased sensitivity and specificity for endometrial cancer are needed to help monitor response to therapy and to detect recurrent disease. Currently, the tumor maker CA125 is utilized in this role with limited value. The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus.Methods. Pre-operative serum samples from surgically staged patients with endometrioid adenocarcinorna of the uterus were analyzed for levels of HE4, SMRP, CA72-4 and CA125. Control samples were obtained from healthy postmenopausal women. Logistic regression models and receiver operating characteristic (ROC) curves were constructed for each tumor marker and for all combinations, with cross-validation analyses to obtain average sensitivities at set specificities of 90%, 95%, and 98%.Results. Serum samples from 156 healthy subjects and 171 patients with endometrial cancer (122 stage 1, 17 stage II, 26 stage III, and 6 stage IV) were analyzed. At a 95% specificity, the sensitivities for differentiating between healthy subjects and all stages of cancer were 45.5% for HE4 and 24.6% for CA125. For stage I disease, HE4 yielded a 17.1% improvement in sensitivity compared with CA125.Conclusion. HE4 is elevated in all stages of endometrial can 100cer and is more sensitive in early-stage endometrial cancer compared to CA125. Further investigation of HE4 as a marker for early detection of recurrent endometrial cancer and monitoring response to therapy is warranted. (c) 2008 Elsevier Inc. All rights reserved.